(HealthDay News) – Use of intermediate-acting non-depolarizing neuromuscular blocking agents during general anesthesia is associated with an increase in the risk of postoperative respiratory ...

MALVERN, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, today ...

Muscle relaxants given to millions of patients during general anaesthesia are associated with an increased risk of serious breathing problems after surgery, finds a study published on bmj.com today.

Baudax Bio, Inc. BXRX announced additional positive data from its phase II study of BX1000, which is used as a neuromuscular blockade (“NMB”) in patients undergoing elective surgery. The efficacy of ...

An ED physician ordered a neuromuscular blocking agent to sedate a combative patient. However, a nurse administered the drug too soon, before the patient could be intubated. The patient arrested and ...

In patients undergoing mechanical ventilation for the acute respiratory distress syndrome (ARDS), neuromuscular blocking agents may improve oxygenation and decrease ventilator-induced lung injury but ...

Neuromuscular blocking agents are frequently administered to pigs used for research. In humans, administration of the drugs is not without risk and may result in accidental awareness under general ...

Eclat Pharmaceuticals announced that it has ended shortages of Bloxiverz (neostigmine methylsulfate) injection for the reversal of the effects of non-depolarizing neuromuscular blocking agents (NMBAs) ...

MALVERN, Pa., July 05, 2017 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care ...

FOR a number of years we have been interested in the neuromuscular blocking properties of bis-onium compounds derived from substituted tropane nuclei, in which linking of the quaternary nitrogens was ...